Interleukin-10 Induces Apoptosis in Developing Mast Cells via a Mitochondrial, STAT3-dependent Pathway by Bailey, Daniel Paul
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2005
Interleukin-10 Induces Apoptosis in Developing
Mast Cells via a Mitochondrial, STAT3-dependent
Pathway
Daniel Paul Bailey
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Medicine and Health Sciences Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1410
 Virginia Commonwealth University 
School of Medicine 
 
 
This is to certify that the dissertation prepared by Daniel Paul Bailey entitled 
"Interleukin-10 Induces Apoptosis in Developing Mast Cells via a Mitochondrial, 
STAT3-dependent Pathway" has been approved by the student advisory committee as 
satisfactory for completion of the dissertation requirement for the degree of Doctor of 
Philosophy. 
 
 
____________________________________________  
John J. Ryan, Ph.D., Director of Thesis/Dissertation, School of Humanities and Sciences 
 
 
____________________________________________  
Thomas F. Huff, Ph.D., Vice Provost of Life Sciences  
 
 
____________________________________________  
Daniel H. Conrad, Ph.D., School of Medicine  
 
 
____________________________________________  
Lawrence B. Schwartz, M.D., Ph.D., School of Medicine 
 
 
____________________________________________  
Christopher L. Kepley, Ph.D., School of Medicine  
 
 
___________________________________________  
Dennis E. Ohman, Ph.D., Chair, Department of Microbiology and Immunology 
 
 
____________________________________________  
Jerome F. Strauss, III, M.D., Ph.D., Dean, School of Medicine  
 
 
___________________________________________  
F. Douglas Boudinot, Ph.D., Dean, Graduate School  
 
 
____________________________________________  
Date 
  
Interleukin-10 Induces Apoptosis in Developing Mast Cells via a Mitochondrial, 
STAT3-dependent Pathway 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
 
By 
Daniel Paul Bailey 
B.S. Virginia Commonwealth University, 2000 
M.S. Virginia Commonwealth University, 2002 
 
 
 
 
 
Director:  John J. Ryan, Ph.D. 
Associate Professor, Department of Biology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
December, 2005
 
 ii
Acknowledgment 
 
 
 I would like to thank Dr. John Ryan for his mentorship.  His enthusiasm, positive 
attitude, guidance and friendship have made this experience unforgettable.  I would also 
like to thank my committee members, Dr. Thomas Huff, Dr. Daniel Conrad, Dr. 
Lawrence Schwartz, and Dr. Christopher Kepley for their guidance with my dissertation.  
I especially would like to thank my coworkers, Andrew Bouton, Mohit Kashyap, Brian 
Barnstein, and Peyman Kabolizadeh for all of their support, assistance, and friendship.  I 
greatly appreciate all of the help from the office staff on the VCU Monroe Park Campus, 
Stephanie Millican, and Bonnie VanDusen who both made working in the biology 
department a great experience.  Also, I would like to thank the office staff of the 
Department of Microbiology and Immunology, Connie Babcock, Nancy Fogg, Bobbie 
Fogg, and especially Martha Crewey for helping me navigate through Graduate School 
successfully.  Lastly, I would like to thank all of my friends and family: my parents, 
Bruce Bailey and Jean Bailey, my brothers, Craig Bailey and Brian Bailey, my 
grandparents, Paul and Alice Pohlman, and my close friends Chris Sargent, Mike and 
Malorie Janis, Mohit and Nitika Kashyap.  Their love and support have helped me 
through the hardest of times. 
 
 
 
SMB 
 iii
Table of Contents 
 
 
 
List of figures.....................................................................................................................iv 
List of models.....................................................................................................................vi 
Abstract.............................................................................................................................vii 
Introduction..........................................................................................................................1 
Materials and methods.......................................................................................................14 
Results................................................................................................................................18 
Discussion..........................................................................................................................83 
Literature cited...................................................................................................................89 
Vita.....................................................................................................................................11 
 iv
List of Figures 
 
 
 
Figure.............................................................................................................................Page 
 
1.  Effects of IL-10 on bone marrow cell numbers in culture............................................20 
 
2.  Time course of IL-10 effects.........................................................................................22 
 
3.  Addition/removal of IL-10 (10 ng/ml) to bone marrow cultures containing IL- 
    3+SCF............................................................................................................................24 
 
4.  IL-10 alters IL-3+SCF-induced differentiation............................................................27 
 
5.  Wright Giemsa histochemical analysis.........................................................................29 
 
6.  Non-Specific Esterase histochemical analysis..............................................................31 
 
7.  IL-10 alters IL-3+SCF-induced Kit/T1ST2  expression...............................................34 
 
8. IL-10 alters IL-3+SCF-induced Kit Fluorescence.........................................................36  
 
9.  IL-10 alters IL-3+SCF-induces T1ST2 Fluorescence..................................................38 
 
10.  IL-10 alters IL-3+SCF induced MAC-1 expression...................................................40 
 
11.  IL-10 alters IL-3+SCF-induced MAC-1 Fluorescence...............................................42 
 
12.  Example histogram of PI DNA staining.....................................................................45 
 
13.  IL-10 increases bone marrow cell apoptosis...............................................................47 
 
14.  Example histogram of Caspase-3 staining..................................................................49 
 
15.  IL-10 enhances Caspase-3 activation..........................................................................51 
 
16.  Example Histogram of Di(OC6)3 Staining..................................................................54 
 
17.  IL-10-mediated apoptosis involves a mitochondrial pathway....................................56 
 
18.  IL-10 induces apoptosis via a p53 and Bcl-2 dependent pathway..............................58 
 
19.  The effect of IL-10 on the growth factor receptor Kit surface expression.................61  
 
20.  The effect of IL-10 on the growth factor receptor Kit fluorescence..........................63 
 v
 
21.  The effect of IL-10 on the growth factor receptor IL-3Rβ surface expression..........65 
 
22.  The effect of IL-10 on the growth factor receptor IL-3Rβ fluorescence....................67 
 
23.  Cells cultured in IL-10 show diminished survival in response to IL-3.......................70 
 
24.  Cells cultured in IL-10 show diminished survival in response to SCF.......................72 
 
25.  STAT3 deletion increases bone marrow cell survival................................................75 
 
26.  Western blot showing deletion of STAT3 protein in STAT3 flox/-;lysMcre cells....77 
27.  Time course of IL-4+IL-10 effects.............................................................................80 
28.  IL-4+IL-10 increases bone marrow cell apoptosis.....................................................82  
 
 
 
 
 
 vi
List of Models 
 
 
 
Model of mast cell homeostasis........................................................................................11 
 vii
 
ABSTRACT 
INTERLEUKIN-10 INDUCES APOPTOSIS IN DEVELOPING MAST CELLS 
VIA A MITOCHONDRIAL, STAT3-DEPENDENT PATHWAY  
By Daniel Paul Bailey 
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2005 
Director: John J. Ryan, Ph.D., Associate Professor, Department of Biology 
 
Objective.  
 The aim of this study was to determine the effects of interleukin-10 on mast cell 
development from bone marrow progenitors. 
Materials and Methods.  
 Unseparated mouse bone marrow cells were cultured in IL-3+SCF, giving rise to 
mast cells and monocytes/macrophages.  The addition of IL-10, and the use of Signal 
Transducer and Activator of Transcription (STAT)3-deficient bone marrow cells were 
employed to measure the effects of IL-10 and STAT3 expression on cell viability, 
proliferation, and differentiation.  Bax-deficient and Bcl-2 transgenic bone marrow cells were 
used to determine the importance of the mitochondria in IL-10-mediated effects. 
 
 
 viii
Overview.   
 Mast cells arise from hematopoietic stem cells and continue development in either 
connective tissue or mucosa.  Th2 cytokines have been implicated in the regulation of mast 
cell development and subsequent function.  Mast cells have also been shown to be essential 
players in many Th2 immune responses.    
 In the following study we investigate the effects of the Th2 cytokine IL-10 on mast 
cell development from isolated bone marrow progenitors.  The addition of IL-10 to whole 
murine bone marrow greatly reduced cell numbers and altered the phenotype of the 
developing progenitor cells.  The reduction in cell numbers was due to apoptosis, as judged 
by DNA fragmentation and caspase activation.  The apoptosis observed included alteration in 
mitochondrial membrane potential.  Furthermore, apoptosis could be reduced by the 
overexpression of Bcl-2 or by ablating p53 expression.  Utilizing a flox/cre system we found 
that IL-10 mediated apoptosis required expression of Stat-3, since Stat-3 deficient bone 
marrow cells did not undergo apoptosis in response to IL-10.  In this study we also observed 
significant alterations in the mast cell growth factor receptors IL-3R and c-kit.  The loss of 
these growth factor receptors may explain the apoptosis induced by IL-10.  These data 
demonstrate the potent regulatory capabilities of Th2 cytokines on mast cells, a central 
effector in the Th2 response.  
 
 
 
 
 
 Introduction 
History of Mast Cells 
 The mast cell was first characterized by Paul Ehrlich in June of 1878.  The 
nomenclature mast cell is derived from the German name originally given to this highly 
granulated cell “mastzelle” which means well-fed cell (1).  Mast cells are rounded, 
mononuclear cells that are heavily granulated.  The granules found within a mast cell 
appear purple when stained with aniline blue dyes, as a result of the reaction of the dye 
with highly-acidic heparin contained within the granules (2).  Mast cells are derived from 
pluripotent CD34+ bone marrow progenitors, and upon exiting the bone marrow 
complete their development in mucosal and connective tissue through a process requiring 
cytokine-regulated trafficking, proliferation, and differentiation (3). 
 The mast cell has been shown to be involved in hypersensitivity reactions, 
autoimmune diseases and innate immunity.  Murine mast cells are used to investigate 
multiple diseases processes, although there are differences between murine and human 
mast cells.  Murine mast cells require IL-3 to differentiate and survive in vitro while 
human mast cells require IL-6 (4).  The cytokine stem cell factor (SCF) is critical for 
mast cell development and survival in both mice and humans.   
 Mast cells are divided into two subsets based on their expression of proteases, in 
both humans and rodents.  In humans, MCTC contain tryptase, chymase, carboypeptidase 
and cathepsin G (5).  MCT express only tryptase.  MCTC are mostly found in the skin and 
mucosa, while MCT are mainly observed in alveoli and epithelium of the intestines and 
airway.  In rodents, they are classified as connective tissue mast cells (CTMC) and 
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mucosal mast cells (MMC).  CTMC express mast cell specific protease (MMCP)-5,6, 
while MMC express MMCP-1-4 (6).   
 
Th2 CELLS 
 Everyday the human body is insulted by a barrage of harmful pathogens and 
allergens.  In order to protect us against this onslaught the immunological response has 
evolved into two distinct arms to recognize and respond to microorgansims and non-self 
antigen.  These are the innate and adaptive immune responses.  The innate arm is the first 
to encounter foreign invasion and responds in a non-specific fashion to antigenic stimuli 
by producing multiple agents to kill or neutralize the foreign agent.  For the most part 
induction of the innate response is sufficient to clear intrusive agents from the body.  
However, in the case that the noxiuos agent is not controlled by the innate response, the 
adaptive response is also engaged.   
At the forefront of this attack lie T lymphocytes that orchestrate the complex 
balance of immunity.  Within the T lymphocyte population, CD4+ T helper-2 (Th2) cells 
are critical effector cells necessary for regulating the humoral immune response to 
allergens and pathogens.  This subset of CD4+ effector T cells develop from naïve CD4+ 
cells during the initial response to antigen in the peripheral lymphoid tissue.  Upon 
antigen presentation via dendritic cells in the lymph node and subsequent T cell 
activation in the presence of interleukin (IL)-4, the naïve CD4+ T cell population will 
develop into IL-4,-5,-6,-10, and -13 producing Th2 cells.  The diverse array of cytokines 
produced by Th2 cells regulates the immune response so that the eliciting agent is 
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neutralized while maintaining a balance of pro-inflammatory and anti-inflammatory 
measures (7).   
 
WHAT ARE Th2 CYTOKINES? 
 Th2 cytokines are predominantly produced by activated CD4+ T cells but can also 
be produced by other cells, including mast cells and macrophages.  The Th2 cytokine 
group is made up of the hematopoietin, and IL-10 families of cytokines.  These cytokines 
have both pro-inflammatory and anti-inflammatory activities.  Th2 cytokines not only 
play an important role in allergic disease and autoimmune disorders but they are also 
important for cell development and maturation.  The striking importance of balancing 
these activities is most obvious in disorders where the immune system is dysfunctional, 
such as allergic and autoimmune disease. 
 
IL-4 
 Interleukin (IL)-4 is produced by Th2 cells (8), mast cells (9), and basophils (10).  
It stimulates proliferation of activated B cells (8), mast cells, and T cells (11).  On B 
cells, IL-4 elicits expression of MHC class II (12), CD23 (13), IgE and IgG1 (14).  IL-4 
also downregulates production of pro-inflammatory cytokines from macrophages, while 
increasing antigen-presenting functions (Reviewed in 15, 16).  Of special importance, IL-
4 induces Th2 development, while inhibiting Th1 development (10, 17).  These activities 
make IL-4 central to the Th2 response, with some dampening effects on cellular 
immunity. 
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 A role for Th2 cytokines such as IL-4 in atopic diseases is attributed to its 
promoting IgE production and Th2 development, although the genetic predisposition for 
mounting an unbalanced Th2 response is incompletely understood.  In addition to asthma, 
IL-4 may be tied to other inflammatory diseases in which the Th2 response is 
dysregulated.  For a review of the roles of IL-4 in allergy, see (18, 19).   For example, 
chronic IL-4 production elicits a lupus-like inflammatory disease in transgenic mice (20).    
 IL-4 signals by binding to the IL-4Rα, in combination with the common gamma 
chain, or in some cases with IL-13Rα1.  Ligand binding conveys cellular signals through 
a number of pathways, including IRS1/2, phosphatidylinositol 3’-kinase (PI3-K), Ras-
MAPK, and the Jak-Stat pathway (Reviewed in 21).  As shown by genetically targeted 
mice, the 94kDa transcription factor Stat6 is necessary for IL-4-mediated Th2 
differentiation and IgE production (22-24).  Stat6 is critical to IL-4 function, as illustrated 
by the similarities between animals made genetically deficient in IL-4 or Stat6 (8, 10, 25, 
26). Thus, Stat6 is considered to be an essential mediator of IL-4 responses.   
 
IL-10  
  Interleukin (IL)-10 was initially identified as cytokine synthesis inhibitory factor 
(27), a potent Th2-derived factor that decreases Th1 cell activation and cytokine 
secretion.  These activities were shown to be partly indirect, through the ability of IL-10 
to dampen monocyte/macrophage antigen presentation, via reduced expression of co-
stimulatory molecules, MHC II antigens, and cytokines (28).  IL-10 is produced by Th2 
cells, Th0 cells, CD45Rblow regulatory T cells, monocyte/macrophages, keratinocytes, 
some B cells, and mast cells (Reviewed in 27).  The importance of IL-10 was perhaps 
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best demonstrated through the creation of IL-10-deficient mice, which develop a Th1-
mediated enterocolitis and have potent Th1 responses (29).  The inhibitory effects of IL-
10 have best been shown in the regulation of the inflammatory activities of macrophages 
and dendritic cells [Reviewed in 30 Moore].   
 The evolutionary importance of IL-10 has been made clear by the identification of 
IL-10 homologues expressed by Epstein-Barr virus, equine herpes virus 2, pox ORF 
virus, and cytomegalovirus (30-35).  Further, an entire family of IL-10-related cytokines, 
including IL-19, IL-20, IL-22, IL-24, and IL-26 has recently been identified, greatly 
increasing the focus on this regulatory factor (reviewed in 36 ).   
 IL-10 signaling has been studied in some depth.  Its heterodimeric, interferon-like 
receptor is widely expressed on hematopoietic cells and other lineages, offering many 
potential targets for IL-10 action. While IL-10 receptor signaling can involve 
phosphatidylinositol 3’-kinase, ribosomal S6 kinase, and members of the AP-1 family 
(reviewed in 28), much focus has been on the role of the Jak-Stat signaling system.  IL-10 
is known to employ Jak1 and Tyk2 to activate Stat3, with activation of Stat1 and Stat5 in 
some systems.  Stat3 has been shown to be the most important IL-10 signaling pathway, 
required for most IL-10 functions and able to directly mimic some IL-10 activities (37-
42).   
 Few cytokines have a stronger link to disease outcomes than IL-10.  In clinical 
trials, IL-10 treatment reduces the symptoms associated with Crohn’s disease, rheumatoid 
arthritis, psoriasis, and hepatitis C infection (43-52).  Productive immunotherapy for 
allergic disease correlates with increased IL-10 production (53-57), and mutations in the 
IL-10 promoter are linked to allergy incidence (58).  In animal models, IL-10 has also 
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been shown to be a potent immunomodulator.  Summarizing these studies, IL-10 
treatment mitigates the severity of pathology in experimental allergic/autoimmune 
encephalomyelitis (EAE) (59-61), non-obese diabetes (62), inflammatory arthritis (63-
69), airway hyperresponsiveness/allergy, and inflammatory bowel disease (IBD) (70).  
These data are supported by the spontaneous IBD that IL-10-deficient mice develop 29).  
Further, anti-IL-10 treatment worsens EAE incidence and severity, and protective therapy 
with IFNγ may induce IL-10 synthesis (71, 72).  Thus, IL-10 has been shown in a broad 
range of studies to possess clinically relevant inhibitory abilities. 
     There are exceptions to the protective role of IL-10.  Owing to its B cell 
stimulatory capabilities, IL-10 may worsen systemic lupus erythematosus (SLE).  In this 
regard, IL-10 levels positively correlate with disease, and anti-IL-10 therapy decreases 
autoantibody production in some mouse models.  Perhaps most importantly, a recent 
clinical trial found that anti-IL-10 treatment significantly improved symptoms in 5 of 6 
patient (73).  Despite these findings, there is also support for a beneficial role for IL-10 in 
SLE.  For example, in a Fas-deficient model of Lupus, IL-10 deficiency worsened disease 
(74), and IL-10 decreased Th2-type autoantibody formation (75).  It appears that the true 
role of IL-10 in SLE may be partly determined by the mechanisms leading to clinical 
disease, particularly with reference to Th1- versus Th2-mediated responses.  On balance, 
IL-10 signaling has clear links to inflammatory disease, and inducing or inhibiting this 
signaling is an area of considerable clinical interest 
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MAST CELLS 
Mast cells were first recognized for their importance in parasite clearance.  In 
contrast to this protective role, the mast cell is best characterized for its role as an effector 
cell of allergic disease.  Recently the importance of mast cells to adaptive immunity has 
expanded.  The mast cell response has been shown to be essential for resistance to 
bacterial infection and involved in the inflammatory responses characteristic of several 
clinical autoimmune conditions including rheumatoid arthritis(76-78), sjogren syndrome 
(79), systemic sclerosis (80), multiple sclerosis (81), thyroid disease (82), chronic 
urticaria (83, 84), pemphigus (85), and atherosclerosis (86).  Mast cell deficiency also 
greatly diminishes inflammation in animal models of multiple sclerosis and heart disease 
(87, 88).  These data support the contention that mast cells participate in both T helper 
cell (Th)1 and Th2 responses.  Given this contribution, the means by which cytokines 
alter the mast cell response is an area of research that may yield clinically important tools 
for treating inflammatory disease. 
 
MAST CELL DEVELOPMENT  
 Mast cells are derived from pluripotent hematopoietic stem cells found in the 
bone marrow.  Recently, Galli et.al. described a cell population in adult mouse bone 
marrow characterized as Lin(-)c-Kit(+)Sca-1(-)-Ly6c(-)-FcepsilonRIalpha(-)- 
CD27(-)beta7(+)-t1ST2(+), that gives rise only to mast cells in culture (89).  This 
population was able to reconstitute the mast cell compartment when transferred into c-kit 
mutant mast cell-deficient mice.  Mast cell committed precursors exit the bone marrow 
and complete their development in connective and mucosal tissues.  In these locations 
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mast cells are positioned to function as sentinel cells of host defense.  The process of 
mast cell development is driven by the activities of IL-3 and stem cell factor (SCF), two 
well-characterized mast cell growth and differentiation factors (3).  With the broadening 
importance of mast cells to immune function and pathology, mast cell development, 
maturation, and function are key areas of interest.  Defining the factors that regulate mast 
cell recruitment to peripheral tissues, maintenance of mast populations, and removal of 
non-essential, or aging mast cells needs further investigation.   
 
MAST CELL ACTIVATION AND FUNCTION 
 Activation of mast cells results in the release of a wide array of biologically active 
preformed and induced compounds that can result in leukocyte chemotaxis, smooth 
muscle contraction in bronchial and gastrointestinal tracts, increased vascular 
permeability and mucus production by goblet cells (90, 91).  Mast cell activation is often 
achieved via the cross-linking and aggregation of IgE receptors by specific antigen (90, 
91).  Mast cells may also be activated via non-IgE signals including direct interaction 
with pathogenic bacteria (92, 93), or bacterial products such as enterotoxin B (94), or 
cholera toxin (92, 95), and components of the complement cascade (96). Compounds 
released by mast cells include preformed vasoactive amines such as histamine and 
serotonin, proteoglycans, proteolytic enzymes and cytokines such as tumor necrosis 
factor (TNF)-a, and interleukin (IL)-16 (97).  In addition, mast cells can be stimulated to 
make three classes of arachidonic acid-derived lipid mediators, including prostaglandin 
D2 (PGD2), leukotrienes (LTC4, LTD4, and LTE4), platelet activating factor (PAF), as 
well as multiple cytokines including IL-1,3,4,5,6,8,9,10,12,13,16,18, GM-CSF, TNF-a, 
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lymphotoxin, macrophage inhibitory protein (MIP)1-a, MIP-1b, TCA-3, leukemia 
inhibitory factor (LIF), transforming growth factor (TGF)-b, and nerve growth factor 
(NGF) (97).  Due to the vast array of mediators produced by mast cells and their frequent 
intersection with the Th2 response, it is important to gain a better understanding of how 
this interaction contributes to the homeostatic regulation of the mast cell population. 
   
EFFECTS OF IL-4 AND IL-10 ON MAST CELLS 
  Many studies find correlations between serum IL-10 and on-going immune 
responses or disease progression.  For example, serum IL-10 levels are elevated for at 
least 5 days during septicemia, with some patients demonstrating up to 2800pg/ml (98, 
99).  Colorectal cancer, breast cancer, B cell lymphoma, and  hepatocellular carcinoma 
patients all show elevated serum IL-10 (100-103) .  This is also true in chronic hepatitis, 
myocardial infarction, Graves disease, and systemic sclerosis (104-107).  In related 
studies using an animal model, Fred Finkelman’s group has shown that IL-4 
concentrations exceeding 10ng/ml are detected following anti-CD3 injection (108), and 
that serum IL-4 concentrations remain elevated for more than 10 days during parasite 
infections (109). Each of these studies demonstrates that local inflammation can increase 
serum cytokine concentrations, possibly affecting cells at considerable distance from the 
site of origin. This is important to understanding mast cell homeostasis, since systemic 
cytokines could be affecting mast cells throughout their otogeny.  This is the rationale for 
our investigations into how Th2 cytokines alter mast cell development, as well as the 
function and survival of differentiated mast cells.  Mast cell responses are well-
established as a central aspect of chronic inflammatory disease.  Our group is focused on 
 10
understanding the mast cell “life cycle” - how its development, function, and survival are 
controlled, and the consequences of losing this balance.  Mirroring classic models, we 
have formed a hypothesis of cytokine-mediated mast cell homeostasis, in which the 
signaling molecules both elicit and limit the mast cell response (Figure 1).  The immune 
responses in which mast cells function are frequently under the control of Th2 
lymphocytes.  Our laboratory has investigated the control of mast cell homeostasis 
through feedback regulation by the Th2 cytokines IL-4 and IL-10, which are important in 
eliciting mast cell–mediated inflammation.   
 IL-4 is a mast cell growth factor (11), and induces FcεRI expression on 
developing human mast cells (110, 111).  These and other activities argue for the pro-
atopic nature of IL-4 in mast cell biology.  But in support of an anti-inflammatory role for 
IL-4 we have found that IL-4 decreases mast cell Kit and FcεRI expression, inhibits IgE-
mediated activation, and induces death of mast cell precursors (112-114).  We find that 
Stat6 activation is both necessary and sufficient to elicit many of these responses (112-
114).  Other groups have reported IL-4-induced apoptosis of human mast cells (115 
Oskeritzain) and have employed our assays to demonstrate inhibitory effects of IL-4 on 
mast cells (112, 116, 117). Central in these assays is the element of timing: IL-4 has no 
inhibitory effects on mast cells until 3 days of stimulation.  Our hypothesis is that this 
timing frames an "inflammatory window" during which mast cells serve their protective 
roles in immunity.   Following this is an "inhibitory window" wherein IL-4 reduces mast 
cell activation, causes arrest and apoptosis of mature cells, and finally kills developing 
precursors (Model of Mast Cell Inflammatory Response). 
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Model of Mast Cell Inflammatory Response 
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  On mast cells, we found that IL-10, like IL-4, inhibits expression and/or function 
of the high affinity receptor for IgE, FcεRI, and Kit (112-114, 118-120).  IL-10 serves as 
a potent inducer of apoptosis in developing mast cells through a STAT-3 dependent 
pathway.  In these studies we observed IL-10 inhibited mast cell survival through 
downregulation of IL-3 and SCF receptors, both critical for mast cell survival and 
proliferation.  We have also found that combined signaling with IL-4 and IL-10 induces 
apoptosis of differentiated mast cells (10, 119).  
 
SUPPORT FOR CYTOKINE-MEDIATED MAST CELL HOMEOSTASIS 
Results from other laboratories support our theory that Th2 cytokines regulate 
mast cell homeostasis.  For example, IL-4-knockout mice have increased basal peritoneal 
mast cell numbers, implying defective homeostasis (121).  A detailed series of studies 
with intestinal pathogens also offers support.  Immunity to helminthe infections is 
accomplished by a time-limited Th2 response accompanied by mast cell hyperplasia in 
the intestine.  This immune response appears to be limited partly by mast cell apoptosis, 
as recently published (122).  However, Stat6-deficient mice, which lack many IL-4 
responses, have a five-fold greater mast cell hyperplasia during such infections (123).  
Mirroring this, we have found that Stat6-deficient mast cells do not undergo IL-4+IL-10-
induced apoptosis (112-114, 116).   
Studies of disease-linked polymorphisms provide additional theoretical support 
for the notion that cytokines regulate mast cell biology.  Mast cells are central effectors of 
allergic inflammation.  Allergy-related polymorphisms of the IL-10 promoter, the IL-4 
promoter, and the IL-4 receptor alpha chain have been noted (54, 124-129).  It is possible 
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that such genetic changes may prevent Th2-mediated mast cell regulation, though these 
effects are unknown. Lastly, chronic mast cell hyperplasia is most notable in mast cell 
neoplasms that involve gain-of-function mutations in Kit (130-132).  Cell lines bearing 
these mutations do not undergo IL-4+IL-10-induced apoptosis (119), and fit a description 
of homeostatic dysregulation, like all neoplasms. 
Loss of homeostatic constraints lies at the root of all chronic diseases. If Th2 
cytokines dampen the mast cell response, our theory predicts that sustained Th2 cytokine 
production should normally limit mast cell-mediated inflammation.  The fact that this 
does not appear to happen in diseases like asthma could be used to argue against our 
theory.  However, we believe that loss of mast cell homeostasis may be part of the disease 
etiology, such that chronic disease represents a departure from the constraints maintained 
in healthy subjects.  Thus our theory will shed light both on normal physiology as well as 
pathophysiology.
 Materials and Methods 
 
Culture System   
Bone marrow cells were extracted from the femurs of C57BL/6x129 mice (“wild type”; 
from Taconic Farms,Germantown, NY), STAT3 flox/-; lysMcre mice (133, 134), Bax-
deficient mice, p53-deficient mice (Jackson Labs, Bar Harbor, ME), or H2K-Bcl-2 
transgenic mice (135).  Cells were cultured at 5x105 cells/ml in complete RPMI medium 
(cRPMI), consisting of RPMI 1640 medium supplemented with 10% FBS, 2mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 1 mM sodium pyruvate (all 
from Biofluids, Rockville, MD) for 21 days.  Cultures contained IL-3 (5 ng/ml) + SCF 
(50 ng/ml), and IL-10 at the indicated concentrations (purchased from R&D Systems, 
Minneapolis). During the culture period, cells were fed every 4-7 days by removing half 
of the culture contents with or without scraping as indicated.  An equal volume of new 
medium and cytokines was replaced into the cultures.  Importantly, in scraped cultures 
that are there was no selection against adherent cells (predominantly macrophages) as is 
frequently the case for mast cell development assays.  As such, these cultures gave rise to 
a mixture of monocyte/macrophages and mast cells.  Prior to harvesting samples for 
analysis, cultures were scraped, so that adherent cells were included in all assessments.  
The efficacy of scraping was determined by examining cultures with an inverted 
microscope, which revealed that nearly all adherent cells were removed from the plate 
surface.  By comparison, cultures that were passaged to remove adherent cells developed 
into virtually pure (>95%) mast cells, based on histochemical analysis and flow 
cytometry staining for FcεRI and Kit.   
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Flow Cytometry Staining 
Samples were obtained by removing a 200µl sample after scraping. Samples were 
washed with phosphate-buffered saline (PBS) containing 3% fetal calf serum (FCS) and 
0.1% sodium azide (FACS Buffer), then incubated with 10µl rat anti-mouse 
FcγRΙΙ/FcγRIII ascites (clone 2.4G2) to prevent non-specific interaction of antibodies 
with IgG receptors. Cells were then stained with FITC-labeled IgG (Southern Biotech. 
Inc., Birmingham, AL), PE-labeled IgG (BD Biosciences Co., San Diego, CA), PE-
labeled anti-Mac-1 (Southern Biotech), FITC-labeled anti-T1/ST2 (Morwell Diagnostics, 
Zurich, Switzerland), PE-labeled anti-Kit (BD Biosciences), FITC-labeled anti-IgE 
(Southern Biotech), FITC-labeled anti-CD13 (BD Biosciences), or PE-labeled  
anti-βIL-3/βc (BD Biosciences).   
 
Assessment of Live Cell Numbers 
To compare the relative number of live cells in each culture condition, samples were 
prepared as described for flow cytometry staining, using 200µl of cells removed from 
each culture.  Samples were analyzed for 45 seconds (time resolution 0.1 seconds) on a 
BD FACscan (BD Biosciences).  Live cell gating was accomplished by forward and side 
scatter parameters, the efficacy of which was confirmed by propidium iodide exclusion.  
Live cell numbers in experimental conditions were compared to cells cultured in IL-
3+SCF (control conditions) to determine a percent change relative to this control group.  
We found this method to be more objective and consistent than similar assessments of 
cell numbers such as trypan blue exclusion. 
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Propidium Iodide Analysis of Apoptosis 
 To detect sub-diploid DNA, a 200µl sample was removed from scraped cultures and 
washed twice with PBS.  Samples were fixed in an ethanol solution and stained with 
propidium iodide in the presence of RNase A as described previously (119).  Each 
sample was analyzed for 45 seconds (time resolution, 0.1 seconds) with a BD 
Biosciences FACScan, with a forward scatter-side scatter gate to exclude cellular debris.  
Percent cells with sub-diploid DNA content (apoptotic cells) was calculated using 
CellQuest software by gating on those cells whose PI fluorescence was less than the 
diploid peak in control cultures. 
 
Di(OC6)3 Staining 
 Di(OC6)3 (Molecular Probes, Eugene, OR) was added to 200µl of cells at 1nM final 
concentration.  Samples were incubated for 30 minutes at 37°C in a CO2 incubator.  The 
cells were then washed twice with PBS and resuspended in 200µl PBS for flow 
cytometric analysis using a forward and side scatter gate. 
 
Histochemical Analysis 
Cell cultures were scraped and 200µl samples were removed, washed twice with 200µl of 
PBS, and centrifuged onto microscope slides (Shandon Cytospin 2, ThermoShandon, 
Pittsburgh, PA).  Slides were stained with Wright Giemsa (WG) (Sigma Aldrich 
Chemicals) or with acid toluidine blue (0.2 % Toluidine Blue, 0.1 M citric acid, in 50 % 
EtOH in dH20).  Non-specific esterase staining was performed using a kit and protocol 
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provided by Sigma (Napthol AS-D Chloroacetate Esterase and α-Naphthyl Acetate 
Esterase, Procedure No. 91).  
 Results 
IL-10 reduces cell numbers in an IL-3 and SCF-rich environment 
 Murine bone marrow cells were cultured in the presence of IL-3+SCF with or 
without IL-10 for 21 days. In these cultures, IL-10 reduced relative cell numbers in a 
concentration-dependent manner, with a 75% decrease when IL-10 was present at 10 
ng/ml (Figure 1).  To determine the kinetics of this effect, samples were measured at 
various time points during the 21 day culture period (Figure 2).  The effects of IL-10 
were not significant during culture days 0-10, but between days 10 and 21 the relative 
cell numbers reduced rapidly (slope = 0.5 days 0-10; slope = -3.2 days 10-21).  The 
inhibitory effects of IL-10 required a relatively long exposure period.  Not only did cell 
numbers remain unchanged for the first 10 days of culture, but removal of IL-10 from 
these cultures during the first 15 days prevented any significant decrease in cell numbers 
when cells were harvested on day 21 (Figure 3).  Likewise, IL-10 added after the first 7 
days of culture had no effect on viable cell numbers when cultures were harvested on day 
21.  Thus IL-10 greatly reduced the survival of developing bone marrow cells, exerting 
its effects with delayed kinetics that required its presence early in differentiation. 
 18
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Figure 1.  
Effects of IL-10 on bone marrow cell numbers in culture.  Concentration-response of IL-
10 effects on viable cell numbers. Bone marrow cells were cultured in IL-3+SCF +/- IL-
10. Cultures were harvested after 21 days and viable cell numbers were 
measured by timed flow cytometric counting as described in Materials and Methods. 
Statistical analysis was conducted using ANOVA pairwise comparison (*p<0.05). Each 
data point represents at least 5 separate experiments. 
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Figure 2.   
Time course of IL-10 effects.  Bone marrow cells were cultured in IL-3+SCF +/- IL-10 at 
10 ng/ml. Viable cell numbers were determined on the indicated days by timed flow 
cytometric counting.  Statistical analysis was conducted using ANOVA pairwise 
comparison (*p<0.05). Each data point represents at least 5 separate experiments. 
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Figure 3. 
Addition/removal of IL-10 (10 ng/ml) to bone marrow cultures containing IL-3+SCF. IL-
10 was added to or removed from cultures containing IL-3+SCF on the days indicated. 
All cultures were harvested on day 21. Viable cell numbers were determined by timed 
flow cytometric counting.  Statistical analysis was conducted using ANOVA pairwise 
comparison (*p<0.05). Each data point represents at least 3 separate experiments.
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Mast cell but not macrophage development is impaired by IL-10 
In addition to inhibiting cell survival, IL-10 may be altering the differentiation 
of developing bone marrow progenitors.  Growth in IL-3+SCF with selection against 
adherent cells gives rise to mast cells; however we wanted to determine the effects of IL-
10 without bias for a specific lineage.  Therefore, these cultures, like those studied in 
Figure 1, were performed without selection. On day 21 of culture, samples were removed 
and assessed by morphological appearance.  This initial analysis revealed that the 
majority of cells had either mast cell or monocyte/macrophage morphology (Figure 4).  
Hence, we also employed specific histochemical stains for the mast cell and macrophage 
lineages.  The percentage of mast cells was significantly decreased in cultures containing 
IL-3+SCF+IL-10 as determined by morphology (Wright Giemsa stain) or by acidic 
toluidine blue staining (Figure 5).  By contrast, the fraction of macrophage-lineage cells, 
indicated by alpha-naphthyl acetate esterase staining, increased significantly (Figure 6).   
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Figure 4.  
IL-10 alters IL-3+SCF-induced differentiation. Bone marrow cells were 
cultured in IL-3+SCF with or without IL-10 for 21 days.  Mast cell or 
monocyte/macrophage morphology was determined by Wright Giemsa (WG), acidic 
toluidine blue (TB) or non-specific esterase (NSE) staining.  Black bar represents 
10µΜ length.  Solid arrowhead indicates mast cell morphology; open arrowhead 
indicates monocyte/macrophage morphology.
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Figure 5. 
Histochemical stains were assessed by 400X light microscopy.  Slides were quantified by 
assessing WG stained slides for cells possessing mast cell morphology, which is depicted 
as percent mast  cells. Percentages are based on at least 100 total counts from at 
least 3 random fields from at least 4 experiments. Statistical analysis was conducted using 
ANOVA pairwise comparison (*p<0.05). 
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Figure 6.   
Histochemial stainss were assessed by 400X light microscopy.  Slides were quantified by 
assessing  NSE slides for NSE-positive staining, which is depicted as percent 
macrophages.  Percentages are based on at least 100 total counts from at least 3 random 
fields from at least 4 experiments.  Statistical analysis was conducted using ANOVA 
pairwise comparison. 
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To further characterize IL-10-induced changes in differentiation, the expression of 
cell surface markers was measured.  Mast cells express the receptor tyrosine kinase Kit 
and the IL-1-related receptor T1/ST2.  Early in our cultures (day 10), before a significant 
decrease in cell numbers occurred, the percentage of cells co-expressing Kit and T1/ST2 
was not significantly altered by the presence of IL-10.  However, by day 21, a point at 
which cell numbers were significantly reduced, IL-10 stimulation had greatly reduced the 
fraction of cells co-expressing Kit and T1/ST2 (Figure 7).  Interestingly, IL-10 did not 
decrease the relative amount of Kit expression on Kit-positive cells (Figure 8), and 
actually increased T1/ST2 expression (Figure 9). In contrast to the effects on mast cell 
markers, IL-10 did not alter the percentage of cells expressing the monocyte/macrophage 
surface antigen CD11b (Mac-1) on either day 10 or 21 (Figure 10), and had no effect on 
the intensity of its expression (Figure 11).    
Based on the combined histochemical and flow cytometric data, it appeared that 
within the population of surviving cells (approximately 25% of the starting population), 
IL-10 significantly reduced the proportion of mast cells and had little effect on 
macrophages derived by culture in IL-3+SCF.  Rather, it had opposing effects on the final 
differentiation patterns of these cells, limiting the expression of toluidine blue-staining 
proteoglycans and mast cell surface antigens, but increasing macrophage esterase 
expression.  Thus while the most overt effects of IL-10 were a decrease in live cells, this 
cytokine also affects cell development.    
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Figure 7.  
IL-10 alters IL-3+SCF-induced suface antigen expression. Bone marrow cells 
were cultured in IL-3+SCF with or without IL-10 for 21 days.  The percentage 
of mast cell surface antigens was determined by flow cytometric analysis, measuring 
expression of Kit and T1/ST2. Statistical analysis was conducted using ANOVA pairwise 
comparison (*p<0.05). Each data point represents at least 4 separate experiments.
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Figure 8.   
IL-10 alters IL-3+SCF-induced suface antigen expression. Bone marrow cells were 
cultured in IL-3+SCF with or without IL-10 for 21 days.  Mean fluorescence intensity of 
the mast cell surface antigen Kit was determined by flow cytometric analysis.  Statistical 
analysis was conducted using ANOVA pairwise comparison (*p<0.05).  Each data point 
represents at least 4 separate experiments. 
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Figure 9.   
IL-10 alters IL-3+SCF-induced suface antigen expression. Bone marrow cells were 
cultured in IL-3+SCF with or without IL-10 for 21 days.  Mean fluorescence intensity of 
the mast cell surface antigen T1ST2 was determined by flow cytometric analysis.  
Statistical analysis was conducted using ANOVA pairwise comparison (*p<0.05).  Each 
data point represents at least 4 separate experiments. 
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Figure 10.  
IL-10 alters IL-3+SCF-induced suface antigen expression. Bone marrow cells 
were cultured in IL-3+SCF with or without IL-10 for 21 days.  The percentage 
of macrophages was determined by flow cytometric analysis, measuring expression of 
CD11b (MAC-1). Statistical analysis was conducted using ANOVA pairwise comparison 
(*p<0.05). Each data point represents at least 4 separate experiments.
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Figure 11.   
IL-10 alters IL-3+SCF-induced suface antigen expression. Bone marrow cells were 
cultured in IL-3+SCF with or without IL-10 for 21 days.  Mean fluorescence intensity of 
the macrophage surface antigen MAC-1 was determined by flow cytometric analysis.  
Statistical analysis was conducted using ANOVA pairwise comparison (*p<0.05).  Each 
data point represents at least 4 separate experiments.
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Apoptosis is enhanced by the presence of IL-10 
 The decrease in cell numbers observed after IL-10 addition could have been the 
result of diminished proliferation or enhanced cell death.  Propidium iodide (PI) DNA 
staining was performed to ascertain if an increase in sub-diploid DNA content correlated 
with the reduction in live cell numbers noted during days 10-21 (Figure 2).  Sub-diploid 
DNA is representative of the DNA fragmentation associated with apoptosis (Figure 12).  
As seen in (Figure 13), IL-10 had no effect on apoptosis on days 0-10, but conveyed a 
sharp and significant increase to include 60% of the population between days 10 and 21.  
Activation of the death-effector enzyme caspase-3 immediately precedes the onset of 
apoptosis (Figure 14).  We measured caspase-3 activation on day 15 and found 
significantly higher activity in cells that had been treated with IL-10 (Figure 15).  These 
data show that the reduction in live cells numbers caused by IL-10 correlated with an 
increase in apoptosis.
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Figure 12.  
IL-10 increases bone marrow cell apoptosis.  Example histogram of PI-DNA staining 
from samples harvested on day 21 of culture in IL-3+SCF (black line) or IL-3+SCF+IL-
10 (gray line) are shown.  Horizontal marker indicates sub-diploid (apoptotic) cells.
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Figure 13.  
IL-10 increases bone marrow cell apoptosis.  PI-DNA staining Flowcytometric 
quantification of samples harvested on day 21 of culture in IL-3+SCF (black line) or IL-
3+SCF+IL-10 (gray line) are shown.   Statistical analysis was conducted using ANOVA 
pairwise comparison (*p<0.05).  Each data point represents at least 4 separate 
experiments. 
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Figure 14.  
IL-10 enhances caspase-3 activation.  Example histogram of caspase-3 staining from 
samples harvested on day 21 of culture in IL-3+SCF (black line) or IL-3+SCF+IL-10 
(gray line) are shown.  Horizontal marker indicates fraction of population with active 
caspase-3.   
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Figure 15.   
IL-10 enhances caspase-3 activation.  Caspase-3 flowcytometric quantification of 
samples harvested on day 21 of culture in IL-3+SCF (black bar) or IL-3+SCF+IL-10 
(gray bar) are shown.  Statistical analysis was conducted using ANOVA pairwise 
comparison (*p<0.05).  Each data point represents at least 4 separate experiments. 
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IL-10 induces changes in mitochondrial membrane stability 
 Changes in mitochondrial membrane potential (∆ψΜ) can occur during apoptosis 
(Figure 16), often resulting from alterations in the Bcl-2 gene family expression or 
function [21].  IL-10-mediated changes in ∆ψΜ were measured via Di(OC3) 6 staining.  
As shown in (Figure 17), IL-10 altered the pattern of Di(OC3)6 staining, with evidence of 
both hypo- and hyper-polarization.  Thus the presence of IL-10 resulted in disruption of 
∆ψΜ.   
 We next employed bone marrow cells from transgenic and gene-deficient mice to 
determine the importance Bcl-2 family proteins and the p53 transcription factor that can 
alter their expression.  Bone marrow cells from mice deficient in pro-apoptotic Bax or 
p53 expression, or from mice overexpressing anti-apoptotic Bcl-2 were cultured in IL-
3+SCF +/- IL-10.  Loss of Bax expression did not alter the IL-10-mediated decrease in 
cell numbers.  By contrast, p53 deficiency or overexpression of Bcl-2 increased survival 
approximately 2-fold; however neither completely reversed the effects of IL-10 (Figure 
18).  These observations indicate that the inhibitory effects of IL-10 correlate with loss of 
normal mitochondrial membrane potential and can be partially corrected by increasing 
Bcl-2 expression or deleting p53.
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Figure 16.  
IL-10-mediated apoptosis involves a mitochondrial pathway.  Representative histogram 
of changes in mitochondrial membrane potential were assessed by Di(OC6)3 staining.  
The area marked M1 indicates hypopolarization and the area marked M2 indicates 
hyperpolarization.  
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Figure 17.   
IL-10-mediated apoptosis involves a mitochondrial pathway.  Quantification of changes 
in mitochondrial membrane potential were assessed by Di(OC6)3 staining. Quantification 
Statistical analysis was conducted using ANOVA pairwise comparison (*p<0.05). Each 
data point represents at least 3 separate experiments. 
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Figure 18.  
IL-10 induces apoptosis via a p53 and Bcl-2 dependent pathway.  WT,  Bax-deficient 
(Bax KO), p53-deficient (p53 KO) and H2K-Bcl-2 transgenic (Bcl-2 Tg) bone marrow 
cells were cultured for 21 days in IL-3+SCF +/- IL-10.  Viable cell numbers were 
assessed on day 21 by timed flow cytometric counting, and calculated as a percentage of 
IL-3+SCF cultures. Statistical analysis was conducted using ANOVA pairwise 
comparison (*p<0.05). Each data point represents at least 3 separate experiments.
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IL-10 inhibits IL-3 Receptor Expression 
 The growth factors IL-3 and SCF promote cell development and survival. 
Inhibition of growth factor signaling has been shown to result in p53-dependent apoptosis 
that proceeds through a mitochondrial pathway, also referred to as the “intrinsic” death 
pathway [21, 22].  Since IL-10 signaling resulted in an apoptotic response coincident 
with changes in ∆ψΜ, and was partially corrected by p53 deletion or Bcl-2 
overexpression, we measured changes in IL-3 and Kit receptor expression during the 
onset of apoptosis. We chose day 15 of culture for these assays, as it was the earliest 
point at which changes in ∆ψΜ were detected.  Importantly, in these assays we cultured 
bone marrow with selection against adherent cells, resulting in purified mast cell cultures.  
This enabled us to measure changes in Kit and IL-3 receptor expression on a purified 
population expressing these receptors.   
 As we had found on day 21 using non-selected cells, IL-10 had no effect on either 
the total percentage of Kit-only expressing cells or Kit expression levels (Figure 19, 20).  
In contrast, IL-10 diminished the expression intensity of the IL-3R beta subunit by more 
than 60%, without altering the percentage of cells expressing this protein (Figure 21,22).  
Thus IL-10 appeared to selectively target the IL-3 receptor beta subunit, decreasing 
expression of this survival receptor in a manner that correlated with apoptosis. 
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Figure 19.  
The effect of IL-10 on growth factor receptor surface expression.  Bone marrow cells 
were cultured in IL-3+SCF +/- IL-10, with selection against adherent cells.  Percentage of 
Kit-positive cells measured by flow cytometric staining with anti-Kit. Statistical analysis 
was conducted using ANOVA pairwise comparison (*p<0.05).  Each data point 
represents at least 3 separate experiments. 
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Figure 20.   
IL-10 alters surface expression of growth factor receptors. Bone marrow cells 
were cultured in IL-3+SCF +/- IL-10, with selection against adherent cells. 
Expression intensity of Kit-positive cells measured by flow cytometric staining with anti-
Kit. Statistical analysis was conducted using ANOVA pairwise comparison (*p<0.05). 
Each data point represents at least 3 separate experiments. 
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Figure 21.  
IL-10 alters surface expression of growth factor receptors.  Percentage of IL-3 receptor-
beta positive cells measured by flow cytometric staining with anti-IL-3 receptor beta . 
Statistical analysis was conducted using ANOVA pairwise comparison (*p<0.05). Each 
data point represents at least 3 separate 
experiments. 
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Figure 22.   
Expression level of IL-3 receptor-beta measured by flow cytometric 
staining with anti-IL-3 receptor beta . Statistical analysis was conducted using ANOVA 
pairwise comparison (*p<0.05). Each data point represents at least 3 separate 
experiments.
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Figure 22. 
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IL-3 and SCF responsiveness is diminished in cells that have been cultured in IL-10 
 Activation of the intrinsic, mitochondrial apoptotic pathway can be triggered by 
loss of growth factor receptor function.  Since changes in survival signaling can occur 
with or without alterations in receptor expression, it was essential that we determine if 
IL-10 disrupted IL-3 and SCF-mediated survival.  To measure these effects, we employed 
short term survival assays.  Bone marrow cells were cultured for 21 days in IL-3+SCF +/- 
IL-10, after which equal numbers of cells were washed and re-plated in decreasing 
concentrations of IL-3 or SCF for 4 days.  The percentage of surviving and apoptotic 
cells was judged by the presence of sub-diploid DNA, as detected by PI-DNA staining.  
As shown in (Figure 23, 24), cells that had previously been cultured in IL-10 were 
significantly less responsive to IL-3 or SCF in these assays.  Under conditions where 55-
70% of the cells previously cultured in IL-3+SCF survived in IL-3 or SCF alone, cells 
previously stimulated with IL-10 showed survival rates of 20%.  These data indicated that 
IL-10 stimulation inhibited survival signaling by both the Kit and IL-3 receptor 
complexes, resulting in a factor-withdrawal response that is consistent with the intrinsic, 
mitochondrial apoptotic cascade we have observed.
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Figure 23.  
Cells cultured in IL-10 show diminished survival in response to IL-3.  Equal numbers of 
cells cultured in IL-3+SCF +/- IL-10 for 21 days were washed and re-plated in decreasing 
concentrations of IL-3 for 4 days. After PI-DNA staining, viable cell numbers were 
measured by timed flow cytometric counting. Statistical analysis was conducted using 
ANOVA pairwise comparison (*p<0.05). Each data point represents at least 3 separate 
experiments.
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Figure 24.  
Cells cultured in IL-10 show diminished survival in response to SCF. Equal numbers of 
cells cultured in IL-3+SCF +/- IL-10 for 21 days were washed and re-plated in decreasing 
concentrations of SCF for 4 days. After PI-DNA staining, viable cell numbers were 
measured by timed flow cytometric counting.  Statistical analysis was conducted using 
ANOVA pairwise comparison (*p<0.05). Each data point represents at least 3 separate 
experiments.
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STAT3 is necessary for IL-10 mediated apoptosis 
 STAT3 is essential for IL-10 receptor signaling [18, 19]  STAT3-deficient mice 
die during embryogenesis [18], precluding their use in our assays of mast cell and 
macrophage survival.  To study the importance of STAT3 in IL-10-mediated apoptosis 
we employed a lineage-restricted cre/lox system in which STAT3 is deleted in the 
macrophage lineage by lysozyme M-driven expression of the cre recombinase [19)  Bone 
marrow from these mice and their littermate controls were cultured in M-CSF +/- IL-10, 
and viable cells numbers were measured by PI-DNA staining and timed flow cytometric 
counting on day 7 of culture. Like its effects on IL-3+SCF-mediated survival, IL-10 
significantly reduced the number of wild type cells cultured in M-CSF.  However, 
STAT3 deletion completely reversed this effect.  In STAT3-deficient cultures, IL-10 
induced a 2-fold increase in viable cell numbers (Figure 25).  We confirmed the loss of 
STAT3 expression in these cultured cells by western blotting (Figure26). These data 
indicate that STAT3 expression is required for the death-inducing effects of IL-10 on 
developing bone marrow cells.
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Figure 25.  
STAT3 deletion increases bone marrow cell survival. Utilizing a Cre/Lox 
System, STAT3 was deleted in cells of the monocyte/macrophage lineage.  Bone 
marrow was cultured for 7 days in M-CSF +/- IL-10 and cell numbers were measured by 
timed flow cytometric analysis. Statistical analysis was conducted using ANOVA 
pairwise comparison (*p<0.05). Each data point represents at least 3 separate 
experiments.
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Figure 26.   
Western blot showing deletion of STAT3 protein in STAT3 flox/-; 
lysMcre cells.
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Figure 26. 
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IL-4 augments IL-10 mediated apoptosis 
  Previous findings by our laboratory have shown that the Th2 cytokine IL-4 can 
also inhibit mast cell development from hematopoietic stem cells (Bailey et al).  We 
sought to determine if the addition of IL-4 to cultures of IL-10 caused any biologically 
significant effect on IL-10 mediated apoptosis.  When whole bone marrow was cultured 
in the presence of IL-10+IL-4 we observed a faster and more significant decrease in 
viable cell numbers as compared to when cultured with only IL-10 (Figure 27).  
Apoptosis was also induced earlier when IL-4 was added to these cultures (Figure 28).  
These findings indicate that IL-4 augments the inhibitory effects of IL-10.  In our 
previous study of the effects of IL-4 on mast cell development we found that STAT6 was 
both necessary and sufficient in mediating IL-4 induced apoptosis.  The combined 
signaling of both STAT3 and STAT6 may enhance the induction of apoptosis.   
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Figure 27.   
Time course of IL-4+IL-10 effects.  Bone marrow cells were cultured in IL-3+SCF +/- 
IL-4, IL-10, or IL-4+IL-10 at 10 ng/ml. Viable cell numbers were determined on the 
indicated days by timed flow cytometric counting.  Statistical analysis was conducted 
using ANOVA pairwise comparison (*p<0.05). Each data point represents at least 5 
separate experiments 
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Figure 27. 
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Figure 28.  
IL-4+IL-10 increases bone marrow cell apoptosis. Bone marrow cells were cultured in 
IL-3+SCF +/- IL-4, IL-10, or IL-4+IL-10 at 10 ng/ml and assessed by PI-DNA staining 
on day 21 culture.  Statistical analysis was conducted using ANOVA pairwise 
comparison (*p<0.05). Each data point represents at least 5 separate experiments 
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Figure 28. 
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Discussion 
 Maintenance of cellular homeostasis is critical for prevention of pathological 
changes observed in cancer, autoimmune disease, and immunodeficiency.  To this end we 
have employed a mast cell model system to investigate immune homeostasis, focusing on 
cytokine mediated regulation of survival and function.  Mast cells participate in a wide 
range of inflammatory responses that are orchestrated by T lymphocytes.  Cytokines such 
as IL-4 and IL-10 produced by T cells and mast cells during an inflammatory response 
regulate mast cell homeostasis at multiple levels.  Our theory is that cytokines such as IL-
4 and IL-10 provide feedback regulation for mast cells in a bi-phasic manner.  During the 
first several days of stimulation IL-4 and IL-10 support mast cell survival, proliferation 
and critical receptors necessary for mast cell activation.  After this inflammatory period, 
these same cytokines inhibit survival, proliferation, maturation, and expression of the 
critical proteins FcERI and c-Kit on mature mast cells.  This regulatory circuit could 
allow mast cells to perform critical protective functions and prevent the establishment of 
infection. 
 The IL-10 receptor is expressed on a variety of hematopoietic cells including B 
cells, T cells, macrophages, and mast cells, where it regulates many aspects of the 
inflammatory response.  We reasoned that changes in systemic IL-10 concentrations 
during inflammatory responses could affect not only mature mast cells and macrophages, 
but their precursors as well.  Importantly, IL-10 has been shown to promote murine mast 
cell proliferation.    For example, Rennick et. al. showed IL-10 to be a cofactor for SCF-
dependent mast cell progenitor growth and maturation (136, 137).  IL-10 was also 
reported to promote the growth of IL-3-dependent mast cell progenitors (138, 139).   In 
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contrast to our study, these experiments employed committed mast cell precursors.  It 
appears likely that the effects of IL-10 may be dependent upon the stage of 
differentiation. In support of this, we found that IL-10-mediated apoptosis of developing 
mast cells required that IL-10 be added to bone marrow progenitors during the first 7 
days of culture, the period during which commitment to the mast cell lineage occurs 
(140). 
 Our focus is how Th2 cytokines like IL-10 and IL-4 alter the mast cell response.  
We have previously shown that both cytokines inhibit mast cell IgE receptor and Kit 
expression, and can combine to induce apoptosis in mature mast cells (112, 119, 120, 
141).  We also found that IL-4 could induce the apoptotic death of developing mast cells 
(115).  Importantly, apoptosis induced by IL-4 in developing mast cells, and by IL-4+IL-
10 in mature mast cells proceeded through a mitochondrial pathway that was blocked by 
Bcl-2 overexpression (115, 141), consistent with a factor withdrawal response 
characterized by the intrinsic pathway for apoptosis.  Given these results and the close 
association with elevated serum IL-10 in a wide range of inflammatory conditions, we 
assessed the role of IL-10 in mast cell progenitor development.   
 
IL-10 Exposure induces apoptosis and changes in cell ontogeny 
 
By studying unseparated bone marrow cells we sought to mimic the 
microenvironment in which mast cell precursors would be exposed to IL-10 during an 
inflammatory response.  Adherent cells, predominantly macrophages, were retained in 
these assays to examine changes in differentiation patterns in a non-discriminatory 
fashion.    The differentiation of cells surviving the 21-day assay period was altered by 
IL-10.  Macrophage maturation was not altered, as judged by the insignificant change in 
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esterase expression (Figure 6), while the percentage of granulated mast cells decreased.  
Thus it appeared that IL-10 decreased macrophage survival while inhibiting mast cell 
development. 
During the 21-day assay period viable cell numbers remained stable for up to 10 
days of culture at which point cell numbers declined significantly.  To determine if the 
duration of exposure to IL-10 related to the observed decrease in cell numbers we 
performed an addition and removal assay.  The addition of IL-10 to cells cultured in     
IL-3+SCF on various days during the assay showed that IL-10 could induce its effects 
when added as late as culture day 5.  When IL-10 was added post day 10, we found that it 
could even promote higher cell numbers.   We also observed that cells could be exposed 
to IL-10 for up to 15 days before IL-10 had an effect on cell numbers.  This data 
promotes the hypothesis that there is a commitment phase of cells to either continued 
lineage development or abortion of development leading to possible loss of cell 
proliferation or cell death.  These data are congruent with observation by Rennick et al 
(136, 137) in which mast cell committed precursors flourished in the presence of IL-10.  
Therefore we believe that by day 10 of culture the cells have committed to the mast cell 
lineage as long as favorable conditions exist. 
This hypothesis is supported by the presence of phenotypical mast cells as 
assessed by histochemical staining and cell surface protein expression.  Our observation 
of relatively low numbers of mast cells on day 21 of culture shows that mast cells are and 
were present in these conditions.  It appears that because of the unfavorable environment, 
mast cells could differentiate but prolonged survival was not attainable.    
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Reduced Cell numbers results from induction of apoptosis and activation of intrinsic 
death pathway 
Apoptosis or programmed cell death is a highly regulated process in which cells 
undergo self-destruction (142-148, 149).  This process is characterized by membrane 
blebbing, cell shrinkage, nuclear condensation, and DNA fragmentation (149).  Apoptosis 
can be activated by the presence of a stimulus or the removal of a stimulus.  Cells 
undergo apoptosis through two major pathways, the extrinsic pathway (death receptor 
pathway) or the intrinsic pathway (the mitochondrial pathway).  The extrinsic pathway is 
initiated via activation of specific receptors on the cell surface, namely TNFα  and FasL.  
These receptors are associated with a death domain complex that associate with and 
cleave caspase-8 thereby activating it (150-151).  The active form of caspase-8 then 
activates executioner/effector caspases, such as caspase-3 leading to cell death (152).      
The intrinsic pathway can be initiated via a variety of stress stimuli including 
UV radiation, DNA damage, and loss of survival signals (153).  In general, the 
mitochondria are engaged in intrinsic cell death through loss of mitochondrial membrane 
stability and subsequent activation of caspase-3.  Mitochondrial hyperpolarization (MHP) 
or increased ∆ΨΜ has been shown to preceed the activation of caspases, 
phophatidylserine (PS) externalization in apoptotic cells.  This initial hyperpolarization is 
followed by mitochondrial membrane hypopolarization and complete disruption of the 
mitochondrial membrane potential.  Maintenance of the mitochondria outer membrane is 
critical for cell survival.  Anti-apoptotic members of the Bcl-2 protein family are 
responsible for ensuring stability of the mitochondria.  Disruption of the outer membrane 
results in the release of cytochrome-c from the mitochondria (154).  The discharge of 
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cytochrome-c activates caspase-9 by aggregation of the adaptor Apaf-1, leading to 
activation of the effector caspase 3 (Reviewed in 142, 155).  Disruption of the 
mitochondrial outer membrane can be initiated via pro-apoptotic proteins such as Bax, 
Bad and Bid (156).  In this study we evaluated the mechanism by which progenitor cells 
undergo apoptosis by focusing on proteins specific to the intrinsic death pathway.  
The most overt effect of IL-10 was a 75% reduction in viable cells, caused by an 
apoptotic cascade that was consistent with the intrinsic pathway mediated by 
mitochondrial damage.  This theory is supported by findings of caspase activation and 
DNA fragmentation occurring coincidental to mitochondrial damage.  Moreover, Bcl-2 
overexpression or p53 deletion partially blocked cell death.  Since IL-3 withdrawal 
induces apoptosis via a mitochondrial pathway accompanied by p53 activation (157), we 
suspected that IL-10 acts to interfere with survival signals conveyed by IL-3 and/or SCF.  
Consistent with this idea, exposure to IL-10 greatly reduced IL-3- or SCF-mediated 
survival.  While IL-10 decreased IL-3 receptor beta chain expression, the loss of Kit 
signaling was not matched by changes in expression.  We suspect that IL-10 induces the 
expression of inhibitory molecules such as members of the SOCS family to dampen IL-3 
and SCF signaling. 
 While IL-10 can signal via several pathways, STAT3 may be the most critical of 
these.  For example, STAT3 deletion greatly impairs IL-10 signaling in macrophages (37, 
40, 41).  Accordingly, we employed a lineage-restricted gene targeting system to examine 
the effects of IL-10 on macrophage survival in the absence of STAT3 expression.  The 
effects of IL-10 were completely reversed in the absence of STAT3, highlighting its 
importance in IL-10-mediated cell death.  Given these findings, we hypothesize that IL-
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10 acts via STAT3 to promote apoptosis in developing mast cells and macrophages, 
killing cells by blocking survival signals.  
The delayed kinetics of the IL-10 response are consistent with an immune 
homeostasis controlled by Th2 cytokines.  We have found that IL-4 and IL-10 inhibit the 
function of mature mast cells only after 3 days of signaling (114, 112, 120), allowing 
sufficient time for a protective inflammatory response, but preventing chronic 
inflammation.  Within 6 days of signaling, mature mast cells are removed by IL-4+IL-10 
through mitochondrially-mediated apoptosis (141).  Finally, mast cell precursors, as well 
as developing macrophages, are halted in their development, pushed into an intrinsic 
apoptosis pathway after 14 days of increased IL-10 levels.  As stated, such prolonged 
increases in circulating IL-10 are noted in a wide range of pathological conditions.  It is 
interesting to note that polymorphisms in the IL-4 and IL-10 promoters, as well as the IL-
4 receptor are linked to the establishment of chronic allergic disease (58, 102, 128, 129).  
Perhaps this pathological immune response results in part from loss of homeostatic 
controls over mast cell function and development.  Our data demonstrate that IL-10 has 
potent STAT3-mediated apoptotic effects on developing mast cells and macrophages that 
may assist in preventing the establishment of chronic inflammation.  Loss of these 
protective effects may underlie chronic inflammatory disease.   
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